Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
January 2021
-
Media ReleaseNovartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccineFirst of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…
-
Media ReleaseNovartis renews WHO medicine donation pledge with aim of ending leprosyNovartis leprosy medicine donation program with WHO extended to 2025 Program has already treated over 7 million patients since 2000 New evidence from contact tracing and preventive treatment…
-
Featured NewsNovartis ranks second in 2021 Access to Medicine Index
Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.
-
Key ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc…
-
Key ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetriebenDer Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD): Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44%…
-
Key ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicamentsChiffre d’affaires net des activités poursuivies1 en hausse de 3% (tcc2, +3% USD): Pharmaceuticals: cette unité opérationnelle a progressé de 5% (tcc), soutenue par Entresto (+44%…
-
Featured NewsNovartis 2020 Financial Results
Novartis announces the company’s fourth quarter and 2020 full year financial results.
-
Digital innovation looks set to dominate the 2021 healthcare agenda
Two Novartis leaders share their perspectives on digital health in 2020 – and the key trends to watch out for over the next 12 months.
-
Media ReleaseNovartis and GSK announce collaboration to support scientific research into genetic diversity in AfricaProject Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients Combined…
-
Media ReleaseNovartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines1 Currently…
-
In The NewsPandemic has been a reset for pharma’s reputation
-
Media ReleaseNovartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGeneAgreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growthNovartis secures development and…
Pagination
- ‹ Previous page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- …
- 152
- › Next page